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Abstract: Platinum resistance seriously impacts on the survival outcomes of patients with ovarian
cancers. Platinum-induced DNA damage is processed through DNA repair. NBS1 is a key DNA repair
protein. Here, we evaluated the role of NBS1 in ovarian cancers. NBS1 expression was investigated
in clinical cohorts (protein level (n = 331) and at the transcriptomic level (n = 1259)). Pre-clinically,
sub-cellular localization of NBS1 at baseline and following cisplatin therapy was tested in platinum
resistant (A2780cis, PEO4) and sensitive (A2780, PEO1) ovarian cancer cells. NBS1 was depleted and
cisplatin sensitivity was investigated in A2780cis and PEO4 cells. Nuclear NBS1 overexpression was
associated with platinum resistance (p = 0.0001). In univariate and multivariate analysis, nuclear NBS1
overexpression was associated with progression free survival (PFS) (p-values = 0.003 and 0.017,
respectively) and overall survival (OS) (p-values = 0.035 and 0.009, respectively). NBS1 mRNA
overexpression was linked with poor PFS (p = 0.011). Pre-clinically, following cisplatin treatment,
we observed nuclear localization of NBS1 in A2780cis and PEO4 compared to A2780 and PEO1
cells. NBS1 depletion increased cisplatin cytotoxicity, which was associated with accumulation of
double strand breaks (DSBs), S-phase cell cycle arrest, and increased apoptosis. NBS1 is a predictor
of platinum sensitivity and could aid stratification of ovarian cancer therapy.
Keywords: NBS1; ovarian cancer; platinum sensitization; biomarker
1. Introduction
Overall survival outcomes for patients with advanced ovarian cancer remains poor
despite platinum-based chemotherapy [1–4]. The development of platinum resistance and
disease recurrence is a formidable clinical problem [5–7]. Although the mechanism of
action of platinating agents (carboplatin, cisplatin) is complex, the cytotoxicity predomi-
nantly is related to their ability to induce intra-strand or inter-strand DNA cross-links in
cancer cells [8]. If unrepaired, the DNA cross-links can get converted to double strand
breaks (DSBs) during replication. Accumulation of DSBs can promote cancer cell death [8].
However, enhanced DNA repair capacity and processing of DSBs can lead to platinum re-
sistance in cancer [9]. Recently, in platinum sensitive sporadic or BRCA germ-line deficient
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ovarian cancers, PARP inhibitor (Olaparib, Niraparib, Rucaparib, Talazoparib) mainte-
nance therapy was shown to improve survival [10]. However, only 50% of patient with
platinum sensitive disease obtain benefit from this approach [11]. Therefore, the search for
biomarker(s), besides BRCA mutation status, that determine platinum sensitivity is highly
desirable in ovarian cancers.
The MRE11-RAD50-NBS1 (MRN) complex is key sensor of DSBs [12–17]. The NBS1
protein (also referred to as NBN, nibrin) is a key component of the MRN complex [17–20].
NBS1 modulates DNA damage response (DDR) by recruiting and activating ATM and ATR
to sites of DNA damage. In addition, NBS1 is also involved in the control of intra-S-phase
checkpoints through the activation of ATM and CHK2 after ionizing radiation (IR). NBS1
null mutations in mice are embryonic lethal. Germ-line mutation in the NBS1 gene causes
Nijmegen breakage syndrome (NBS), a rare autosomal recessive disorder characterized by
cancer predisposition, microcephaly, growth retardation, immunodeficiency, and radio sen-
sitivity. NBS1 mutations and polymorphisms can increase risk of many cancers including
ovarian cancers [17–21]. We hypothesized a role for NBS1 in ovarian cancer pathogenesis
and response of platinum therapy.
2. Experimental Section
2.1. Clinical Study
2.1.1. NBS1 Protein Expression in Ovarian Cancers
The expression of NBS1 was evaluated on tissue microarrays of 331 consecutive
epithelial ovarian cancers treated at Nottingham University Hospitals (NUH) between 1997
and 2010. This study was carried out in accordance with the declaration of The Helsinki
and ethical approval which was obtained from the Nottingham Research Ethics Committee
(REC Approval Number 06/Q240/153). Patients were comprehensively staged as per
the International Federation of Obstetricians and Gynecologists (FIGO) Staging System
for Ovarian Cancer. Overall Survival was calculated from the operation date until the
1st of October 2016, when any remaining survivors were censored. All patients received
platinum based chemotherapy. Platinum resistance was defined as patients who had
progression during first-line platinum chemotherapy or relapse within 6 months after
completion of chemotherapy. Progression-free survival was calculated from the date of the
initial surgery to disease progression or from the date of the initial surgery to the last date
known to be progression-free for those censored. Patient demographics are summarized in
Supplementary Table S1.
2.1.2. Tissue Microarray (TMA) and Immunohistochemistry (IHC)
Tumors were arrayed in tissue microarrays (TMAs) constructed with 2 replicate
0.6 mm cores from the tumors. Immunohistochemical staining was preformed using the
Thermo Fisher Scientific Shandon Sequenza chamber system (REF: 72110017, Cheshire,
UK), in combination with the Novolink Max Polymer Detection System (RE7280-K: 1250
tests, Buffalo Grove, IL, USA), and the Leica Bond Primary Antibody Diluent (AR9352,
Buffalo Grove, IL, USA), each used according to the manufacturer’s instructions (Leica
Microsystems Buffalo Grove, IL, USA). The TMA slides were deparaffinized with xylene
and then rehydrated through five decreasing concentrations of alcohol (100%, 90%, 70%,
50%, and 30%) for two minutes each. Pre-treatment antigen retrieval was carried out on
the TMA sections using sodium citrate buffer (pH 6.0) and heated at 95 ◦C in a microwave
(Whirlpool JT359 Jet Chef 1000W, UK) for 20 min. A set of slides were incubated with the
primary anti-NBS1 rabbit monoclonal antibody (N3162, Sigma, Gillingham, Dorset, UK),
at a dilution of 1:200, for 60 min at room temperature. Negative (by omission of the primary
antibody and IgG-matched serum) and positive controls were included in each run.
2.1.3. Evaluation of Immune Staining
Whole field inspection of the core was scored, and the subcellular localization of each
marker was identified (nuclear, cytoplasm, cell membrane). Intensities of subcellular com-
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partments were each evaluated and grouped as follows: 0 = no staining, 1 = weak staining,
2 = moderate staining, 3 = strong staining. The percentage of tumor cells in each category
was estimated (0–100%). Histochemical score (H-score) (range 0–300) was calculated by
multiplying the intensity of staining and the percentage of staining. A median H-score of
≤80 and ≤90 was used as the cut-off for high NBS1 nuclear and cytoplasmic expression,
respectively. Not all cores within the TMA were included for IHC analysis due to missing
cores or absence of tumor cells.
2.1.4. Statistical Analysis
Correlation with clinical and pathological characteristics using categorized data was
calculated using Chi-squared test. All tests were 2-tailed. Survival rates were determined
using Kaplan–Meier method and compared by the log-rank test. All analyses were con-
ducted using Statistical Package for the Social Sciences (SPSS, version 22, Chicago, IL, USA)
software for windows. p value <0.05 was identified as statistically significant.
2.1.5. NBS1 Transcript in Ovarian Cancers
NBS1 mRNA expression was assessed in a publicly available online gene expression
dataset of 1259 ovarian cancer patients treated with platinum-based chemotherapy from 15
previously published studies and available at ‘http://kmplot.com/analysis/index.php?p=
service&cancer=ovar’.
2.2. Pre-Clinical Study
2.2.1. Cell Lines and Tissue Culture
PEO1 (BRCA2-deficient) and PE04 (BRCA2-proficient) were purchased from Amer-
ican Type Culture Collection (ATCC, Manassas, VA, USA). A2780 (platinum sensitive)
A2780cis (platinum resistant) were purchased from Sigma Aldrich (Gillingham, UK). Cells
cultured in RPMI (R8758, Merck, Gillingham, Dorset, UK) supplemented with 1% Penicillin-
Streptomycin (P4333, Merck Gillingham, Dorset, UK) and 10% FBS (F4135, Merck Gilling-
ham, Dorset, UK). All cell lines were maintained in a humidified incubator at 37 ◦C in a 5%
CO2 atmosphere.
2.2.2. Nuclear/Cytoplasmic Extracts and Western Blot Analysis
Cells were collected by trypsinization, washed with PBS, and centrifuged at 1000×
g for 5 min. The extraction of nuclear and cytoplasmic lysates were preformed using the
NE-PER Nuclear and Cytoplasmic Extraction Reagents (78,833, Thermo Fisher, Cheshire,
UK). Extracts were quantified using BCA protein quantification kit and protein levels
were checked by western blot. Samples were run on SDS-bolt gel (4–12%) bis-tris. Mem-
branes were then incubated with primary antibodies as follows: NBS1 (1:500, N3162,
sigma, Gillingham, Dorset, UK), YY1 (1:1000, ab109,228), ß-actin (1:1000, ab8226), GADPH
(1:1000, ab9485). Membranes were then washed and incubated with Infrared dye-labelled
secondary antibodies (LiCor) (IRDye 800CW Donkey Anti-Rabbit IgG (926-32213) and
IRDye 680CW Donkey Anti-Mouse IgG (926-68072)) at dilution of 1:10,000 for 60 min.
Membranes were scanned with a LiCor Odyssey machine (700 and 800 nm, Cambridge,
UK) to determine protein levels.
2.2.3. Protein Quantification
The Pierce BCA kit assay by Thermo Fisher Scientific was used for protein quantifi-
cation. The standard curve was performed with BSA (working range 25 to 2000 µg/mL)
following manufacturer’s instructions. Samples were then added to a 96-well micro plate
and 200 µL of working reagent (50 parts of BCA Reagent A with 1 part of BCA Reagent B)
was added either to samples or standard curve. The plate was incubated at 37 ◦C for half an
hour in the dark, and the absorbance was measured by FLUOstar OPTIMA, UK/Infinite®
F50 (Cheshire, UK) microplate reader at 590 nm. Standards and unknown samples were
performed in duplicate.
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2.2.4. Transient Knockdowns of NBS1
NBS1 (ID S9292) and the validation construct of NBS1 (ID S9293) siRNAs oligonu-
cleotides were purchased from Invitrogen. Lipofectamine 3000 reagent (L3000015, Invitro-
gen, Cheshire, UK) was used according to the manufacturer’s protocol. Briefly, cells were
plated at 50–60% confluency in T25 flasks overnight. In the following day, cells were trans-
fected with 20 nM of siRNA oligonucleotide or scrambled SiRNA oligonucleotide control
(4390843, Thermo Fisher, Cheshire, UK) in Opti-MEM media (31985-062, Gibco, Merck,
Gillingham, Dorset, UK). The efficiency of transfection was confirmed using western blot.
2.2.5. Clonogenic Assays
In the clonogenic assay, 32 cells/cm2 were seeded in 6-well plates and left at 37 ◦C
in a 5% CO2 atmosphere. Cisplatin (kindly provided by Nottingham University Hospital,
Nottingham, UK) was added at the indicated concentrations and the plates were left at
37 ◦C in a 5% CO2 atmosphere for two weeks. The plates were then washed with PBS,
fixed and stained, and colonies were counted.
2.2.6. DSB Accumulation, Cell Cycle and Apoptosis Analysis by Flow Cytometry
1 × 105 cells per well were seeded in 6-well plates overnight. Cells were treated
with cisplatin (1 µM) for A2780 cells and (5 µM) for A2780 cis cells. After 24 h, cells were
trypsinized and washed with ice cold PBS and then fixed in 70% ethanol for at least 30 min.
After removal of the fixative solution by centrifugation cells were stained with anti-phospho
Histone (γH2AX) Ser139. Cells were then treated with RNase and DNA content were
stained with 10 ug/mL propidium iodide (Sigma Aldrich) in PBS. For apoptosis detection,
cells were collected by trypsinization after 24 h washed and analyzed using annexinV
detection kit (BD biosciences). Samples were analyzed on FC500 flow cytometer (Beckman
Coulter, High Wycombe, UK), and data were analyzed using Weasel software (version
3.7.1., Helsinki, Finland).
2.2.7. Statistical Analysis
Data analysis was conducted on GraphPad Prism 7 software (version 5). To compare
between two groups, Student’s T-tests analysis was performed. One-way ANOVA was per-
formed to compare between more than two groups (variances analyses). Two-way ANOVA
was used to analyze two variables, such as Annexin V analysis and cell cycle analysis. All
experiments were expressed as means ± standard deviation S.D. of three independent
experiments. The p-values < 0.05 = *, p-value < 0.01 = ** & p-value < 0.001 = ***.
2.2.8. Next Generation Sequencing and Bioinformatics
Genomic DNA was extracted from cell lines using the PicoPure™ DNA Extraction Kit
(Thermo Fisher, Cheshire, UK). Next generation sequencing was used to identify genomic
variants in platinum sensitive (A2780) and platinum resistant derivatives (A2780cis). The
SureSelect All Exon V5 kit (Agilent Technologies, Santa Clara, CA, USA) was used to
enrich for protein coding regions and sequencing performed using an Illumina NextSeq500
sequencer with paired end reads (150 bp) and a minimum of 80 million reads generated
per sample. Contaminating adapter sequences and low-quality sequences were processed
using Skewer [22]. Quality processed reads were aligned to the HG19 reference genome
using BWA [23], duplicate alignments identified and processed using PicardTools, and re-
alignment completed using the Abra assembly based realigner [24] to enhance detection
of insertion/deletion variants. Variant calling and filtering was completed using Sam-
tools/Bcftools (Version 1.3.1) [25]. Variants, in variant call format (VCF), associated with
platinum resistance were identified using Vcftools [26]. Variants were annotated and func-
tional significance assessed using the Ensembl Variant Effect Predictor tool [27]. Library
preparation and sequencing was conducted by Source Biosciences (Nottingham, UK).
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3. Results
3.1. NBS1 Overexpression and Platinum Resistant Aggressive Ovarian Cancers
We investigated the clinicopathological significance of NBS1 protein expression by
immunohistochemistry (Figure 1A) in a clinical cohort of human ovarian cancers. Patient
demographics are summarized in Supplementary Table S1. NBS1 protein expression was
evaluable in 225 tumors. NBS1 nuclear overexpression was seen in 56/225 (28.5%) tumors
and was significantly associated with platinum resistance (p = 0.0001) (Table 1), shorter
progression free survival (PFS) (p = 0.003) (Figure 1B), and poor OS (p = 0.035) (Figure 1C).
High cytoplasmic NBS1 expression was linked to serous cystadenocarcinoma (p = 0.00004)
(Supplementary Table S2) but did not influence survival (Figure 1D,E). In multivariate
analysis (Table 2), Nuclear NBS1 was independently associated with PFS (p = 0.017) and
OS (p = 0.009).
For additional validation, we evaluated clinical significance of NBS1 mRNA expres-
sion in a publicly available data set (http://kmplot.com/analysis/index.php?p=service&
cancer=ovar) of ovarian cancers (n = 1259). At the transcriptomic level, NBS1 mRNA
overexpression was significantly associated with poor PFS (p = 0.011) (Figure 1F) but did
not influence on OS (p = 0.11) (Figure 1G).
Figure 1. NBS1 and epithelial ovarian cancers. (A) Immunohistochemical staining of NBS1 in ovarian cancers. (B) Kaplan-
Meier curve for NBS1 nuclear protein expression and progression free survival (PFS) in ovarian cancer. (C) Kaplan-Meier
curve for NBS1 nuclear protein expression and overall survival (OS) in ovarian cancer. (D) Kaplan-Meier curve for
NBS1 cytoplasmic protein expression and PFS in ovarian cancer. (E) Kaplan-Meier curve for NBS1 cytoplasmic protein
expression and OS in ovarian cancer. (F) Kaplan-Meier curve for NBS1 mRNA expression and PFS in ovarian cancer.
(G) Kaplan-Meier curve for NBS1 mRNA expression and OS in ovarian cancer. Scale bar = 50 µM, red line= high expression,
black line = low expression.
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Table 1. NB1 protein expression and platinum resistance in sporadic ovarian cancer.
NBS Protein Expression (Nuclear) p-Value
Low High
0.0001Sensitive 131 (74.9%) 44 (25.1%)
Resistant * 5 (31.3%) 11 (68.8%)
NBS Protein Expression (Cytoplasmic) p-Value
Low High
0.676Sensitive 97 (55.4%) 78 (44.6%)
Resistant * 8 (50%) 8 (50%)
* = Platinum resistance was defined as patients who had progression during first-line platinum chemotherapy or
relapse within 6 months after completion of chemotherapy.
Table 2. Multivariate analysis.
Progression Free Survival (PFS)
Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
NBS1 (Nuclear) 0.017 1.803 1.111 2.925
NBS1 (cytoplasmic) 0.476 1.187 0.741 1.903
Tumor Stage 0.000 2.296 1.762 2.992
Overall Survival (OS)
Sig. Exp(B) 95.0% CI for Exp(B)
Lower Upper
NBS1 (nuclear) 0.009 1.746 1.147 2.658
NBS1 (cytoplasmic) 0.612 0.902 0.605 1.344
Tumor Stage 0.000 2.160 1.727 2.700
Taken together, the data suggest that NBS1 could be a predictor of platinum resistance
and poor clinical outcome in patients. We proceeded to pre-clinical functional investigations.
3.2. Sub-Cellular Localization of NBS1 in Ovarian Cancer Cells Following Cisplatin Therapy
A2780 cell is platinum sensitive cell line which was established from previously
untreated ovarian cancer patient. A2780cis cell is a platinum resistant cell line developed by
continuous exposure of the A2780 cell to increasing doses of cisplatin. PEO1 is a platinum
sensitive (BRCA2-deficient) cell line which was derived from a poorly differentiated serous
adenocarcinoma patient who was treated with platinum agents. PEO4 platinum resistant
(BRCA2-proficient) cell line was derived from a malignant effusion from the peritoneal
ascites of the same patient after the development of clinical resistance to platinum therapy.
We first confirmed platinum sensitivity (A2780, PEO1) and resistance (A2780cis, PEO4) by
clonogenic assays (Figure 2A). NBS1 protein levels in nuclear and cytoplasmic extracts at
baseline and following 48 h cisplatin treatment were then investigated in A2780, A2780cis,
PEO1, and PEO4 cells (Figure 2B). In platinum resistant A2780cis and PEO4 cells, platinum
treatment increased nuclear sub-cellular localization of NBS1 compared to in platinum
sensitive A2780 and PEO1 cells (Figure 2C). However, no significant alterations were seen
for NBS1 cytoplasmic expression in A2780, A2780cis, PEO1, and PEO4 cells (Figure 2D).
The results indicate that accumulation of nuclear NBS1 in A2780cis and PEO4 cells could
contribute to cisplatin resistance.
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Figure 2. Sub-cellular localization of NBS1 following cisplatin in ovarian cancer cells. (A) Clonogenic
assay showing Cisplatin sensitivity in A2780, PEO1 compared to A2780cis and PEO4 cells. (B) NBS1
level nuclear and cytoplasmic extracts in platinum resistant (A2780cis, PEO4) and platinum sensitive
(A2780, PEO1) cells treated with 5µM cisplatin. Lysates collected 48 h post-treatment. (C) NBS1
nuclear level quantification A2780, A2780cis, PEO1, and PEO4 cells. (D) NBS1 cytoplasmic level quan-
tification A2780, A2780cis, PEO1, and PEO4 cells. UN = untreated, T = treated. ‘**’ = p value < 0.001.
3.3. NBS1 Variant Profiling in A2780, A2780cis, PEO1, and PEO4 Cells
As NBS1 mutation or polymorphic variants are linked with increased cancer risk [17–21],
we performed targeted deep sequencing for NBS1 variants in A2780, A2780cis, PEO1 and
PEO4 cells. Ensembl VEP was used to analyze the effect and location of variants using
the HG19/GRCh37 genome version. The platinum resistant A2780cis cell line harbors
two novel missense mutations Gly214Arg and Asn209Tyr affecting the NBS1 function
(ENST00000265433.3). These changes result in a charge and volume substitutions, respec-
tively. Mutations in adjacent amino acids have been described in melanoma, uterine and
colorectal cancers. There is no crystal structure for this region of NBS1, and little functional
knowledge about this domain is available. However, based on homology, we observed
that this region of the protein may mediate interaction with the Sp100, a potent tumor
suppressor [28]. Together, the data provides evidence of NBS1 mutant ovarian cancer cells.
We have also investigated Mre11 and Rad50 variants in ovarian cancer cells. In the
parental A2780 line, two unique variants were identified (A: 5:131893147-131893147, a novel
variant predicted to alter splicing; B: 5:131977963-131977963, rs1804670, a synonymous
variant). The Platinum-resistant A2780cis harbors a novel unique variant at 5:131973821-
131973821 which is predicted to introduce Ala→Asp amino acid substitution. This variant
is located within the ATPase domain of RAD50. While the Ala→Asp substitution is similar
in size and volume, the introduction of an acidic aspartic acid may influence substrate
access to the ATPase domain. No variants were identified for Mre11.
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3.4. NBS1 Depletion and Platinum Sensitivity
To evaluate the predictive significance of NBS1, we then proceeded to generate tran-
sient knockdowns (KD) of NBS1 using siRNA constructs in platinum resistant A2780cis
cells (Figure 3A,B). In clonogenic assays, NBS1_KD_A2780cis cells were significantly sensi-
tive to cisplatin compared to scrambled control (Figure 3C). We also confirmed platinum
sensitization using second siRNA construct to deplete NBS1 in A2780 cis cells (Figure 3D–F)
compared to scrambled controls. Increased platinum cytotoxicity in NBS1 depleted cells
was associated with DSB accumulation (Figure 3G), S-phase cell cycle arrest (Figure 3H),
and increased apoptosis (Figure 3I) compared to scrambled controls. For further validation,
we depleted NBS1 in PEO4 cells using siRNA (Figure 4A,B). In clonogenic assays, as ex-
pected, NBS1_KD_PEO4 cells (Figure 4C) were sensitive to cisplatin treatment compared to
controls. Increased sensitivity was associated with DSB accumulation (Figure 4D), S-Phase
arrest (Figure 4E), and increased apoptotic cells (Figure 4F). Taken together, the clinical
and pre-clinical data provides evidence that NBS1 is a predictor of platinum sensitivity in
epithelial ovarian cancers.
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‘***’ = p < 0.0001.
4. Discussion
Platinum resistance is a clinical challenge during ovarian cancer therapy [6]. The
MRE11-RAD50-NBS1 (MRN) complex is the first responder to DSBs [12–14]. NBS1 has
a vital role in repairi g DSBs via non-hom log us and joini g (NHEJ) and homologous
recombination (HR) [17–20]. Clinical and pre-clinical evidence pr sented here provides
evidence that NBS1 is a predictor of platinum sensitivity in o aria cancers.
In clinical cohort of ovarian cance , we obs ved that high nuclear expression was
associated with platinum resistance and poor PFS in patients. Our da a concurs with a
previous study in Asian ovarian cancer patients, where NBS1 overexpression was shown
to be associated with aggressive phenotype and poor survival [29]. Although this study
did not report separate nuclear and cytoplasmic expression, overall NBS1 expression was
associated with advanced stage, serous histology, high grade, and residual tumor in that
study [29]. In the current study, only cytoplasmic overexpression of NB1 was associated
with serous cancers. Interestingly, another study has demonstrated that low NBS1 expres-
sion was observed in low-grade ovarian tumors [30]. NBS1 overexpression was also linked
to aggressive phenotypes in oral squamous cell carcinoma (OSCC) [31], head and neck can-
cer [32], uveal melanoma [33], gastric cancer [34], and colorectal cancer [35]. However, all
these studies including ours are retrospective, which is a limitation. Although prospective
studies will be required, taken together, the data provides clinical evidence that NBS1 is a
promising predictive biomarker in solid tumors. Another limitation of our study is that
we have not DNA sequenced individual tumors to identify any genetic variants of Mre11,
Rad50, nor NBS1 genes.
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In pre-clinical studies, we observed that depletion of NBS1 increased platinum sen-
sitivity. This supports a model for platinum sensitivity were a reduction in NBS1 levels
disrupts the stability of MRN complex, thereby impairing DNA damage recognition and
repair. Persistent cisplatin induced DNA intra-strand and inter-strand cross link during
replication will result in replication arrest, generation and accumulation of DSBs, and
apoptosis. Consistent with this model, we observed DSB accumulation, S-phase arrest
and increased apoptotic cells in NBS1 depleted cells compared to controls. A limitation to
our study is that we investigated transient knock-down of NBS1 using siRNA. Evaluation
in stable KD (using shRNAs) or CRISPR knock out system and in vivo studies will be
required to validate our findings in ovarian cancers. Interestingly, in head and neck cancer
models, molecular disruption of NBS1 increased cisplatin sensitivity in xenograft models,
providing in vivo evidence that NBS1 is a predictive biomarker in solid tumors [36,37].
A further limitation to the pre-clinical study is that we did not directly monitor DDR
functional status in NBS1 deficient cells using assays, such as genomic scar assays [38].
However, as a surrogate marker of DSB accumulation, we quantified the percentage of
γH2AX positive cells as a marker of DNA damage by flow cytometry [39] in control and
NBS1 deficient cells before and after cisplatin treatment.
In platinum sensitive sporadic ovarian cancers, PARP inhibitor maintenance therapy
significantly improves PFS in patients [10]. Although BRCA germ line mutation is a strong
predictor of platinum sensitivity and benefits from PARP inhibitors maintenance therapy,
biomarkers of benefit in sporadic ovarian cancers are yet to be defined. In the current
study, we have shown that NBS1 deficiency is a predictor of platinum sensitivity. McCabe
et al., previously, have shown that NBS1 deficient human SV40- transformed immortal
fibroblasts were sensitive to PARP inhibitor treatment compared to isogenic NBS1 proficient
fibroblasts [40]. In NBS1, deficient breast cancer cell line models were also sensitive to
PARP inhibitors in another study [41]. Taken together, the data would suggest that NBS1
depletion is not only a predictor of platinum sensitivity but could also aid in defining those
patients who could benefit from PARP inhibitor maintenance therapy.
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